Company profile
IMMUNOME INC.
NASDAQ:IMNMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VAREGACESTAT | phase2_3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06855264 | phase1 | completed | 2025-02-24 | 2025-04-08 | Immunome, Inc. | A Cardiac Liability Study of Varegacestat in Healthy Participants |
| NCT06845852 | phase1 | completed | 2025-02-25 | 2025-03-11 | Immunome, Inc. | A Phase 1 Mass Balance Study of Varegacestat |
| NCT07505771 | phase1 | recruiting | 2026-06-19 | 2029-12-01 | Immunome, Inc. | A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer |
| NCT06823167 | phase1 | recruiting | 2025-02-26 | 2028-05-01 | Immunome, Inc. | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer |
| NCT07578571 | phase1 | recruiting | 2026-05-21 | 2029-01-01 | Immunome, Inc. | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer |
FDA applications (0)
No records yet.